NCT05094986

Brief Summary

This pilot study aims to test the feasibility of the following effectiveness and cost-effectiveness evaluation using Real-World Data.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
605

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 8, 2021

Completed
18 days until next milestone

First Posted

Study publicly available on registry

October 26, 2021

Completed
Last Updated

February 18, 2022

Status Verified

February 1, 2022

Enrollment Period

3 months

First QC Date

October 8, 2021

Last Update Submit

February 2, 2022

Conditions

Keywords

Pilot StudyFeasibility StudyComplex InterventionReal-World DataCardiovascular DiseaseDiabetes Mellitus

Outcome Measures

Primary Outcomes (5)

  • Rate of clinical registries related to diabetes mellitus II

    Rate of registries recorded five months before and after the prescription of: * Glycated haemoglobin * Glomerular filtrate * Blood glucose

    5 months before and after recruitment

  • Rate of clinical registries related to dyslipidemia

    Rate of registries recorded five months before and after the prescription of: * Total colesterol * HDL cholesterol * LDL colesterol

    5 months before and after recruitment

  • Rate of clinical registries related to hypertension

    Rate of registries recorded one to two months before and after the prescription of: * Systolic blood pressure * Diastolic blood pressure

    2 months before and after recruitment

  • Rate of clinical registries related to cardiovascular risk

    Rate of registries recorded five months before and after the prescription of: • REGICOR

    5 months before and after recruitment

  • Rate of use of services

    Rate of use of services recorded five months before and after the prescription of: * Visits to primary care (nurse, GP) * Referrals to secondary care * Productivity losses (sick leave days) * Outpatient diagnostic tests

    5 months before and after recruitment

Secondary Outcomes (3)

  • Active diagnosis registry

    5 months before and after recruitment

  • Missing registries

    5 months before and after recruitment

  • Outliers registries

    5 months before and after recruitment

Study Arms (2)

Intervention group: IMA Intervention

EXPERIMENTAL

General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies).

Behavioral: Initial Medication Adherence (IMA) Intervention

Control group

ACTIVE COMPARATOR

Healthcare professionals from the control group prescribed medication and provided information as usual.

Other: Usual Care

Interventions

The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.

Intervention group: IMA Intervention

Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.

Control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary healthcare professionals and pharmacists who:
  • Agree to participate in the pilot study.
  • Primary care patients who:
  • Are prescribed a new treatment of cardiovascular disease o diabetes by a GP who participates in the clinical trial.
  • Are \>18 years old.
  • Do not reject to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

CAP Cornellà de Llobregat (La Gavarra)

Cornellà de Llobregat, Barcelona, 08940, Spain

Location

Centro de Asistencia Primaria (CAP) Dr. Pujol i Capsada (CAP Pujol i Capsada)

el Prat de Llobregat, Barcelona, 08820, Spain

Location

CAP Dr. Bartomeu Fabrés Anglada Gava 2

Gavà, Barcelona, 08850, Spain

Location

CAP Florida Nord (CAP la Florida)

L'Hospitalet de Llobregat, Barcelona, 08905, Spain

Location

CAP Florida Sud (CAP la Florida)

L'Hospitalet de Llobregat, Barcelona, 08905, Spain

Location

Related Publications (1)

  • Corral-Partearroyo C, Sanchez-Vinas A, Gil-Girbau M, Penarrubia-Maria MT, Aznar-Lou I, Serrano-Blanco A, Carbonell-Duacastella C, Gallardo-Gonzalez C, Olmos-Palenzuela MDC, Rubio-Valera M. Improving Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care: Pilot trial of a complex intervention. Front Public Health. 2022 Dec 6;10:1038138. doi: 10.3389/fpubh.2022.1038138. eCollection 2022.

MeSH Terms

Conditions

Medication AdherenceCardiovascular DiseasesDiabetes Mellitus

Interventions

Methods

Condition Hierarchy (Ancestors)

Patient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehaviorGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Investigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
PC patients: Patients from the intervention PCCs received the IMA intervention but were not aware of the group they were assigned to.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Quality and Patient Safety

Study Record Dates

First Submitted

October 8, 2021

First Posted

October 26, 2021

Study Start

November 1, 2020

Primary Completion

January 30, 2021

Study Completion

June 30, 2021

Last Updated

February 18, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

The research team is not the data owner as they are only re-using information that is the property of the public health institutions in Catalonia. Consequently, meta-data cannot be published by the authors nor data can be identified with a DOI.

Locations